Changes in the Expression of DNMTs Before and After Treatment with Methotrexate (MTX)/Mercaptopurine (6-MP) in B-Cell ALL Children

نویسندگان
Imanei-Avaz, Mahmoud ID 1
Hashemi, Azam Sadat ID 2
Ghasemi, Nasrin ID 3
Pourrajab, Fatemeh ID 4
Hekmati Moghaddam, Seyed Hossein ID 5
Barzegar, Kazem ID 6
Vakili, Mahmood ID 7

1 International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

2 Hematology & Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

3 Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

4 Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

5 Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

6 English Language Department, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

7 MD, MPH, Associate Professor in Community Medicine, Health Monitoring Research Center, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

doi
10.18502/ijpho.v14i2.15267
چکیده

Background: DNA methylation is catalyzed by DNA methyltransferases (DNMTs) which are encoded by DNMT1, DNMT3A, and DNMT3B. DNMTs play a major role in the abnormal methylation of tumor suppressors and cancer-related genes. Herein, this study explored the expression profile of DNMTs in pediatric patients with B-cell acute lymphoblastic leukemia (ALL), before ...

کلیدواژه‌ها
DNA Methyltransferases (DNMTs), Methotrexate (MTX), Mercaptopurine (6-MP)